These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36547236)

  • 1. Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.
    Shibeeb S; Ajaj I; Al-Jighefee H; Abdallah AM
    Hematol Rep; 2022 Dec; 14(4):377-388. PubMed ID: 36547236
    [No Abstract]   [Full Text] [Related]  

  • 2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.
    Rajendran K; Krishnasamy N; Rangarajan J; Rathinam J; Natarajan M; Ramachandran A
    J Med Virol; 2020 Sep; 92(9):1475-1483. PubMed ID: 32356910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of convalescent plasma as a therapy for SARS-CoV-2: A systematic review and meta-analysis.
    Choudhuri AH; Duggal S; Singh J; Biswas PS
    J Anaesthesiol Clin Pharmacol; 2022 Jul; 38(Suppl 1):S22-S33. PubMed ID: 36060163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
    Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
    Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.
    Peng HT; Rhind SG; Beckett A
    JMIR Public Health Surveill; 2021 Apr; 7(4):e25500. PubMed ID: 33825689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
    Jeyaraman P; Agrawal N; Bhargava R; Bansal D; Ahmed R; Bhurani D; Bansal S; Rastogi N; Borah P; Naithani R;
    Transfus Apher Sci; 2021 Jun; 60(3):103075. PubMed ID: 33574010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.
    Bansal V; Mahapure KS; Mehra I; Bhurwal A; Tekin A; Singh R; Gupta I; Rathore SS; Khan H; Deshpande S; Gulati S; Armaly P; Sheraton M; Kashyap R
    Front Med (Lausanne); 2021; 8():624924. PubMed ID: 33898477
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.
    Biernat MM; Kolasińska A; Kwiatkowski J; Urbaniak-Kujda D; Biernat P; Janocha-Litwin J; Szymczyk-Nużka M; Bursy D; Kalicińska E; Simon K; Mazur G; Wróbel T
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33800528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders.
    Lanza F; Agostini V; Monaco F; Passamonti F; Seghatchian J
    Clin Hematol Int; 2021 Sep; 3(3):77-82. PubMed ID: 34820612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.
    Barreira DF; Lourenço RA; Calisto R; Moreira-Gonçalves D; Santos LL; Videira PA
    Front Med (Lausanne); 2021; 8():660688. PubMed ID: 33889590
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis.
    Wenjing L; Yuanzheng F; Li JY; Tang LV; Yu H
    Aging (Albany NY); 2020 Dec; 13(1):1498-1509. PubMed ID: 33323550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
    Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
    Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis.
    Jorda A; Kussmann M; Kolenchery N; Siller-Matula JM; Zeitlinger M; Jilma B; Gelbenegger G
    Front Immunol; 2022; 13():817829. PubMed ID: 35197981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.